X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (17051) 17051
Publication (1763) 1763
Book Review (540) 540
Book Chapter (49) 49
Conference Proceeding (13) 13
Dissertation (6) 6
Magazine Article (5) 5
Data Set (4) 4
Presentation (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
open-label (15432) 15432
index medicus (11072) 11072
humans (10734) 10734
oncology (5982) 5982
female (4951) 4951
male (4541) 4541
double-blind (3896) 3896
middle aged (3491) 3491
chemotherapy (3463) 3463
treatment outcome (3299) 3299
adult (3109) 3109
pharmacology & pharmacy (3030) 3030
aged (2841) 2841
cancer (2781) 2781
care and treatment (2685) 2685
multicenter (2210) 2210
clinical trials (1989) 1989
efficacy (1907) 1907
1st-line treatment (1890) 1890
drug therapy (1890) 1890
analysis (1774) 1774
safety (1699) 1699
therapy (1684) 1684
patients (1592) 1592
trial (1547) 1547
medicine & public health (1542) 1542
research (1541) 1541
psychiatry (1477) 1477
mutation (1464) 1464
immunotherapy (1403) 1403
metastasis (1361) 1361
antineoplastic agents - therapeutic use (1342) 1342
clinical neurology (1321) 1321
survival (1278) 1278
health aspects (1245) 1245
aged, 80 and over (1197) 1197
antineoplastic combined chemotherapy protocols - therapeutic use (1196) 1196
animals (1116) 1116
review (1107) 1107
hematology (1099) 1099
adolescent (1089) 1089
placebo-controlled trial (1061) 1061
lung cancer (1060) 1060
cancer therapies (1051) 1051
medical research (1042) 1042
medicine, general & internal (1035) 1035
open-label trial (1013) 1013
randomized controlled trials as topic (1000) 1000
lung neoplasms - drug therapy (967) 967
tumors (952) 952
randomized controlled-trial (877) 877
young adult (874) 874
disease-free survival (872) 872
phase-iii trial (862) 862
prognosis (861) 861
carcinoma, non-small-cell lung - drug therapy (837) 837
studies (837) 837
cell lung-cancer (835) 835
gefitinib (831) 831
neurosciences (824) 824
erlotinib (801) 801
surgery (800) 800
retrospective studies (791) 791
risk factors (784) 784
child (782) 782
clinical trials as topic (780) 780
usage (779) 779
dosage and administration (777) 777
melanoma (773) 773
internal medicine (772) 772
lung cancer, non-small cell (771) 771
drug therapy, combination (750) 750
phase-iii (740) 740
protein kinase inhibitors - therapeutic use (727) 727
abridged index medicus (714) 714
phase-ii (708) 708
immunology (703) 703
medicine, experimental (702) 702
phase-ii trial (700) 700
quality-of-life (696) 696
docetaxel (691) 691
article (687) 687
medicine, research & experimental (685) 685
double-blind method (678) 678
respiratory system (677) 677
hematology, oncology and palliative medicine (668) 668
quality of life (659) 659
children (658) 658
breast cancer (657) 657
endocrinology & metabolism (655) 655
epidermal growth factor (654) 654
drug administration schedule (645) 645
adenocarcinoma (632) 632
lung neoplasms - genetics (627) 627
antibodies, monoclonal - therapeutic use (623) 623
molecular targeted therapy (616) 616
targeted therapy (610) 610
randomized-trial (609) 609
combination (605) 605
pharmacokinetics (605) 605
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (16619) 16619
German (212) 212
French (118) 118
Spanish (62) 62
Italian (9) 9
Portuguese (9) 9
Turkish (8) 8
Polish (7) 7
Japanese (6) 6
Russian (5) 5
Chinese (3) 3
Korean (3) 3
Czech (2) 2
Hungarian (2) 2
Icelandic (2) 2
Slovenian (2) 2
Esperanto (1) 1
Georgian (1) 1
Welsh (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
American Heart Journal, ISSN 0002-8703, 2017, Volume 190, pp. 12 - 18
Background Oral anticoagulation prevents ischemic strokes in patients with atrial fibrillation. Early detection of atrial fibrillation and subsequent... 
Cardiovascular | FIBRILLATION | CARDIAC & CARDIOVASCULAR SYSTEMS | STROKE PREVENTION | WARFARIN | CLINICAL-IMPLICATIONS | AMERICAN-COLLEGE | CARDIAC MONITOR | RISK | OPEN-LABEL | TEMPORAL RELATIONSHIP | ISCHEMIC-STROKE | Prospective Studies | Follow-Up Studies | Humans | Male | Thiazoles - administration & dosage | Atrial Fibrillation - physiopathology | Aspirin - administration & dosage | Factor Xa Inhibitors - administration & dosage | Incidence | Time Factors | Female | Stroke - epidemiology | Vitamin K | Heart Rate | Stroke - prevention & control | Pyridines - administration & dosage | Survival Rate - trends | Double-Blind Method | Administration, Oral | Atrial Fibrillation - drug therapy | Risk Factors | Europe - epidemiology | Treatment Outcome | Disease-Free Survival | Stroke - etiology | Atrial Fibrillation - epidemiology | Aged | Fibrinolytic Agents - administration & dosage | Stroke (Disease) | Care and treatment | Anticoagulants (Medicine) | Stroke patients | Atrial fibrillation | Cardiac patients | Implants, Artificial | Prosthesis | Anticoagulants | Therapy | Cardiac arrhythmia | Surgical implants | Aspirin | Stroke | Coagulation | Strokes | Patients | Bleeding | Risk factors | Vitamins | Artifacts | Fibrillation | Ischemia | Defibrillators | Pacemakers | Safety engineering | Electrocardiography | Heart diseases | Trial Design
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 03/2015, Volume 10, Issue 3, pp. 486 - 491
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 8, pp. 990 - 998
Summary Background Optimum management strategies for patients with advanced non-small-cell lung cancer (NSCLC) with acquired resistance to EGFR tyrosine-kinase... 
Hematology, Oncology and Palliative Medicine | TYROSINE KINASE INHIBITORS | MULTICENTER | ONCOLOGY | ADENOCARCINOMA | ACQUIRED-RESISTANCE | OPEN-LABEL | AFATINIB | ERLOTINIB | GEMCITABINE | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Prospective Studies | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Cisplatin - administration & dosage | Receptor, Epidermal Growth Factor - metabolism | Time Factors | Adult | Female | Quinazolines - administration & dosage | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Genetic Predisposition to Disease | Lung Neoplasms - enzymology | Drug Administration Schedule | Administration, Oral | Carcinoma, Non-Small-Cell Lung - genetics | Europe | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Pemetrexed | Disease Progression | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Phenotype | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Asia | Glutamates - administration & dosage | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Biomarkers, Tumor - genetics | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Infusions, Intravenous | Mutation | Guanine - administration & dosage | Medical colleges | Chemotherapy | Strategic planning (Business) | Genetic aspects | Product development | Lung cancer, Non-small cell | Gefitinib | Cancer
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 3, pp. 345 - 356
Journal Article
JAMA, ISSN 0098-7484, 12/2015, Volume 314, Issue 23, pp. 2535 - 2543
Journal Article
JAMA, ISSN 0098-7484, 12/2017, Volume 318, Issue 23, pp. 2306 - 2316
Journal Article
Lancet, The, ISSN 0140-6736, 2017, Volume 389, Issue 10075, pp. 1195 - 1205
Journal Article